<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kodiak Sciences Inc — News on 6ix</title>
<link>https://6ix.com/company/kodiak-sciences-inc</link>
<description>Latest news and press releases for Kodiak Sciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kodiak-sciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358e9578dffbe2df10146e.webp</url>
<title>Kodiak Sciences Inc</title>
<link>https://6ix.com/company/kodiak-sciences-inc</link>
</image>
<item>
<title>Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value</description>
</item>
<item>
<title>Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-positive-topline-results-in-glow2-the-second-phase-3-study-in-diabetic-retinopathy-demonstrating-superiority-of-zenkudatm-tarcocimab-tedromer-over-sham</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-positive-topline-results-in-glow2-the-second-phase-3-study-in-diabetic-retinopathy-demonstrating-superiority-of-zenkudatm-tarcocimab-tedromer-over-sham</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5%</description>
</item>
<item>
<title>Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/final-apex-phase-1b-clinical-results-kodiaks-ksi-101-macular-edema-secondary</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/final-apex-phase-1b-clinical-results-kodiaks-ksi-101-macular-edema-secondary</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-44th-annual-jp-morgan-healthcare-conference-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-closing-184-million-public-offering-common-stock-including</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-closing-184-million-public-offering-common-stock-including</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-pricing-upsized-public-offering-common-stock-2025-12-16</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-pricing-upsized-public-offering-common-stock-2025-12-16</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-proposed-public-offering-common-stock-2025-12-15</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-proposed-public-offering-common-stock-2025-12-15</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-third-quarter-2025-financial</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the</description>
</item>
<item>
<title>Kodiak Sciences to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-upcoming-investor-conferences-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-upcoming-investor-conferences-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/follow-data-kodiaks-ksi-101-apex-study-showed-continued-strengthening-clinical-effect</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/follow-data-kodiaks-ksi-101-apex-study-showed-continued-strengthening-clinical-effect</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with</description>
</item>
<item>
<title>New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/new-data-kodiaks-ksi-101-apex-study-reinforce-its-clinically-meaningful-vision-gains</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/new-data-kodiaks-ksi-101-apex-study-reinforce-its-clinically-meaningful-vision-gains</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye</description>
</item>
<item>
<title>Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-participate-upcoming-scientific-conferences-highlighting-ksi-101</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-participate-upcoming-scientific-conferences-highlighting-ksi-101</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences to Present at American Chemical Society Fall 2025</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-american-chemical-society-fall-2025-2025-08-19</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-american-chemical-society-fall-2025-2025-08-19</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-second-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-second-quarter-2025</guid>
<pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the</description>
</item>
<item>
<title>Kodiak Sciences to Host Investor R&D Day on July 16, 2025</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-host-investor-rd-day-july-16-2025-2025-07-10</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-host-investor-rd-day-july-16-2025-2025-07-10</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to</description>
</item>
<item>
<title>Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-ksi-101-highlights-2025-congress-international-ocular</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-ksi-101-highlights-2025-congress-international-ocular</guid>
<pubDate>Wed, 25 Jun 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and</description>
</item>
<item>
<title>Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-2025-jefferies-global-healthcare-conference-2025-05-29</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-present-2025-jefferies-global-healthcare-conference-2025-05-29</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and</description>
</item>
<item>
<title>Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-first-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-first-quarter-2025-financial</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the</description>
</item>
<item>
<title>Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-data-arvo-2025-highlight-power-and-versatility-abc-platform</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-data-arvo-2025-highlight-power-and-versatility-abc-platform</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and</description>
</item>
<item>
<title>Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-0</link>
<guid isPermaLink="true">https://6ix.com/company/kodiak-sciences-inc/news/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-0</guid>
<pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the</description>
</item>
</channel>
</rss>